CA2251604A1 - Human hematopoietic stem and progenitor cell antigen and methods for its use - Google Patents
Human hematopoietic stem and progenitor cell antigen and methods for its useInfo
- Publication number
- CA2251604A1 CA2251604A1 CA002251604A CA2251604A CA2251604A1 CA 2251604 A1 CA2251604 A1 CA 2251604A1 CA 002251604 A CA002251604 A CA 002251604A CA 2251604 A CA2251604 A CA 2251604A CA 2251604 A1 CA2251604 A1 CA 2251604A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- sequence
- reagent
- ligand
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract 18
- 239000000427 antigen Substances 0.000 title claims abstract 12
- 102000036639 antigens Human genes 0.000 title claims abstract 12
- 108091007433 antigens Proteins 0.000 title claims abstract 12
- 210000000130 stem cell Anatomy 0.000 title claims abstract 11
- 238000000034 method Methods 0.000 title claims 17
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract 17
- 108010005465 AC133 Antigen Proteins 0.000 claims abstract 11
- 102000005908 AC133 Antigen Human genes 0.000 claims abstract 11
- 210000004027 cell Anatomy 0.000 claims abstract 10
- 210000001185 bone marrow Anatomy 0.000 claims abstract 5
- 230000001605 fetal effect Effects 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 2
- 210000004185 liver Anatomy 0.000 claims abstract 2
- 210000005259 peripheral blood Anatomy 0.000 claims abstract 2
- 239000011886 peripheral blood Substances 0.000 claims abstract 2
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 239000003446 ligand Substances 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 3
- 230000027455 binding Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000009260 cross reactivity Effects 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 210000005260 human cell Anatomy 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims 2
- 239000006249 magnetic particle Substances 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 abstract 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 abstract 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 abstract 1
- 210000004700 fetal blood Anatomy 0.000 abstract 1
- 102000044493 human CDCA4 Human genes 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/838—Marrow; spleen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
Claims (47)
1. An antibody that specifically binds to AC133 antigen, of which antigen the amino acid sequence is shown in SEQ ID NO:2.
2. An antibody according to claim 1, wherein said antibody is a monoclonal antibody produced by a hybridoma cell line.
3. A monoclonal antibody according to claim 1, wherein said antibody is induced through contralateral immunization.
4. A method for enrichment of hematopoietic stem or progenitor cells or both, said method comprising:
combining a mixed population of human cells comprising hematopoietic stem or progenitor cells or both with a reagent that specifically binds to AC133 antigen, of which antigen the amino acid sequence is shown in SEQ ID NO:2; and selecting for those cells that bind said reagent;
wherein said selected cells are enriched in hematopoietic stem or progenitor cell activity or both, depending on whether said mixed population of human cells contained hematopoietic stem or progenitor cells or both, respectively.
combining a mixed population of human cells comprising hematopoietic stem or progenitor cells or both with a reagent that specifically binds to AC133 antigen, of which antigen the amino acid sequence is shown in SEQ ID NO:2; and selecting for those cells that bind said reagent;
wherein said selected cells are enriched in hematopoietic stem or progenitor cell activity or both, depending on whether said mixed population of human cells contained hematopoietic stem or progenitor cells or both, respectively.
5. A method according to claim 4, further comprising:
combining said mixed population of human cells with a reagent that specifically recognize at least one of the cell surface markers CD90, CD117 and HLA-DR; and selecting for those cells that are positive for said at least one of said cell surface markers.
combining said mixed population of human cells with a reagent that specifically recognize at least one of the cell surface markers CD90, CD117 and HLA-DR; and selecting for those cells that are positive for said at least one of said cell surface markers.
6. A method according to claim 4, wherein said reagent is an antibody or an antibody mixture.
7. A method according to claim 6, wherein at least one of said antibodies is fluorochrome conjugated.
8. A method according to claim 7, wherein said selecting with said fluorochrome conjugated antibodies is by flow cytometry.
9. A method according to claim 6, wherein at least one of said antibodies is conjugated to magnetic particles.
10. A method according to claim 9, wherein said selecting with said magnetic particle conjugated antibodies is by high gradient magnetic selection.
11. A substantially pure population of hematopoietic progenitor cells, wherein said cells are bound to a reagent that specifically binds to AC133 antigen, of which antigen the amino acid sequence is shown in SEQ ID NO:2.
12. A substantially pure population of hematopoietic progenitor cells according to claim 11, wherein said reagent is a monoclonal antibody.
13. A substantially pure population of hematopoietic progenitor cells according to claim 11, wherein said progenitor cells are obtained from human fetal liver.
14. A substantially pure population of hematopoietic progenitor cells according to claim 11, wherein said progenitor cells are obtained from human peripheral blood.
15. A substantially pure population of hematopoietic progenitor cells according to claim 11, wherein said progenitor cells are obtained from human bone marrow.
16. A substantially pure population of hematopoietic progenitor cells according to claim 15, wherein said bone marrow is adult.
17. A substantially pure population of hematopoietic progenitor cells according to claim 15, wherein said bone marrow is fetal.
18. An isolated nucleic acid molecule which comprises a sequence having an amino acid coding region for AC133 as set forth in Figure 12 (SEQ ID NO: 1), with the proviso that if said molecule is an RNA molecule, U replaces T in said sequence of said molecule.
19. An isolated nucleic acid molecule which comprises a sequence which is at least 90% identical to the amino acid coding region for AC133 as set forth in Figure 12 (SEQ ID NO:
1), with the proviso that if said molecule is an RNA molecule, U replaces T in said sequence of said molecule.
1), with the proviso that if said molecule is an RNA molecule, U replaces T in said sequence of said molecule.
20. An isolated nucleic acid molecule which comprises a sequence which is a subsequence of the amino acid coding region for AC133 as set forth in Figure 12 (SEQ ID NO: 1) and is at least 14 nucleotides in length, with the proviso that (i) if said molecule is an RNA molecule, U replaces T in said sequence of said molecule, and (ii) said sequence is not nucleotides 347-667, 1564-1696, or 2010-2386 of SEQ ID NO: 1.
21. An isolated nucleic acid molecule which comprises a sequence complementary to said sequence of a molecule according to any of claims 18 to 20.
22. An isolated nucleic acid molecule which consists essentially of DNA encoding the amino acid sequence of AC133 shown in SEQ ID NO: 2.
23. An expression vector comprising a nucleic acid sequence of claim 18.
24. A cell transfected with the molecule of claim 23.
25. An isolated polypeptide, wherein said polypeptide comprises: (1) a first amino acid sequence of AC133 as set forth in SEQ ID NO:2; (2) a second amino acid sequence wherein said second sequence is a subsequence of said first sequence and is at least 6 amino acids in length; or (3) a third sequence in which at least one amino acid of said first or second sequences is replaced by a different amino acid, with the proviso that said amino acid replacement is a replacement of one acidic residue for another, one basic residue for another, one non-polar residue for another, one uncharged polar residue for another, or one aromatic residue for another, with the proviso that said third sequence is at least 90% identical to said first or second sequence.
26. The isolated polypeptide of claim 25, wherein said polypeptide comprises said first sequence.
27. The isolated polypeptide of claim 25, wherein said polypeptide comprises said second sequence.
28. The isolated polypeptide of claim 25, wherein said polypeptide comprises said third sequence.
29. The polypeptide of claim 25 complexed to a ligand.
30. The polypeptide complex of claim 29, wherein said ligand is an antibody.
31. An isolated polypeptide, wherein said polypeptide comprises the amino acid sequence from extracellular N-terminus, aa 20-107; first transmembrane region, aa 107-126;
first cytoplasmic loop, aa 127-157; second transmembrane region, aa 158-179; first extracellular loop, aa 180-435;
third transmembrane region, aa 436-454; second cytoplasmic loop, aa 455-480; fourth transmembrane region, aa 481-503;
second extracellular loop, aa 504-792; fifth transmembrane, aa 793-816; or cytoplasmic C-terminus, aa 817-865; of SEQ ID
NO:2.
first cytoplasmic loop, aa 127-157; second transmembrane region, aa 158-179; first extracellular loop, aa 180-435;
third transmembrane region, aa 436-454; second cytoplasmic loop, aa 455-480; fourth transmembrane region, aa 481-503;
second extracellular loop, aa 504-792; fifth transmembrane, aa 793-816; or cytoplasmic C-terminus, aa 817-865; of SEQ ID
NO:2.
32. A method for identifying a ligand that binds to human hematopoietic stem cells, comprising detecting binding of said ligand with the polypeptide of claim 25.
33. A reagent that specifically binds to the polypeptide of claim 25.
34. The reagent of claim 33, wherein said reagent is selected from the group consisting of monoclonal and polyclonal antibodies.
35. The reagent of claim 33, wherein said reagent is a physiological or synthetic ligand.
36. The polypeptide of claim 25, wherein said polypeptide is not glycosolated.
37. The polypeptide of claim 25, wherein said polypeptide is glycosolated.
38. In a method of isolating hematopoietic stem cells using a cell separation technique based on identification of stem cells by selective binding of a ligand to an antigenic marker on said stem cell, an improvement which comprises:
utilizing as said antigenic marker AC133 antigen, of which antigen the amino acid sequence is shown in SEQ ID NO:2.
utilizing as said antigenic marker AC133 antigen, of which antigen the amino acid sequence is shown in SEQ ID NO:2.
39. The method of claim 38, wherein said ligand is an antibody.
40. The method of claim 38, wherein said ligand binds to an extracellular region of said AC133 antigen.
41. The method of claim 38, wherein said ligand binds to extracellular N-terminus, aa 20-107; first extracellular loop, aa 180-435; or second extracellular loop, aa 504-792; of SEQ
ID NO:2.
ID NO:2.
42. The method of claim 38, wherein said ligand has been identified by determining whether compounds in a group of est compounds bind to said AC133 antigen and selecting said ligand from among compounds that bind specifically to said AC133 antigen with less than 10% crossreactivity with any antigen present on mature blood cells.
43. The method of claim 38, wherein crossreactivity is measured by a competitive binding assay between pure AC133 antigen, said ligand, and said suspected crossreactive antigen using concentrations of AC133 antigen and said ligand where said ligand half-saturates binding to AC133.
44. A ligand for AC133 identified by the method of claim 32.
45. A reagent that binds specifically to AC133 antigen, of which antigen the amino acid sequence is shown in SEQ ID NO:2, with less than 5% crossreactivity with any antigen present on mature blood cells.
46. The reagent of claim 45, wherein said reagent is attached to a surface or to a detectible label.
47. The reagent of claim 45, wherein said label is a fluorescent label.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/639,891 US5843633A (en) | 1996-04-26 | 1996-04-26 | Characterization of a human hematopoietic progenitor cell antigen |
| US08/639,891 | 1996-04-26 | ||
| US08/842,382 US6455678B1 (en) | 1996-04-26 | 1997-04-23 | Human hematopoietic stem and progenitor cell antigen |
| US08/842,382 | 1997-04-23 | ||
| PCT/US1997/006930 WO1997041224A1 (en) | 1996-04-26 | 1997-04-25 | Human hematopoietic stem and progenitor cell antigen and methods for its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2251604A1 true CA2251604A1 (en) | 1997-11-06 |
| CA2251604C CA2251604C (en) | 2012-05-29 |
Family
ID=27093419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2251604A Expired - Lifetime CA2251604C (en) | 1996-04-26 | 1997-04-25 | Human hematopoietic stem and progenitor cell antigen and methods for its use |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US6455678B1 (en) |
| EP (1) | EP0953046B1 (en) |
| JP (3) | JP3908279B2 (en) |
| AT (1) | ATE435282T1 (en) |
| AU (1) | AU720938B2 (en) |
| CA (1) | CA2251604C (en) |
| DE (1) | DE69739480D1 (en) |
| DK (1) | DK0953046T3 (en) |
| ES (1) | ES2327691T3 (en) |
| WO (1) | WO1997041224A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111560053A (en) * | 2020-06-17 | 2020-08-21 | 清华大学深圳国际研究生院 | CD133 antagonistic polypeptide, derivative and application thereof |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132017A1 (en) | 1996-12-09 | 2002-09-19 | Moore Jeffrey G. | Composition and method for preserving progenitor cells |
| US6991794B1 (en) | 1997-06-24 | 2006-01-31 | Imclone Systems Incorporated | Progenitor cell preservation factors and methods for and products of their use |
| US6310195B1 (en) | 1997-06-24 | 2001-10-30 | Imclone Systems Incorporated | Nucleic acid encoding a lectin-derived progenitor cell preservation factor |
| US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| CA2369319A1 (en) * | 1999-03-15 | 2000-09-21 | Eos Biotechnology, Inc. | Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| AU784361C (en) * | 1999-12-30 | 2007-03-15 | Imclone Systems Incorporated | Progenitor cell preservation factors and related methods and products |
| US6566502B1 (en) | 2000-01-28 | 2003-05-20 | Eos Biotechnology, Inc. | Methods of diagnosing cancer, compositions, and methods of screening for cancer modulators |
| US6455668B1 (en) | 2000-01-28 | 2002-09-24 | Eos Biotechnology, Inc. | Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| CA2400319C (en) | 2000-03-15 | 2008-09-16 | Orbus Medical Technologies Inc. | Coating that promotes endothelial cell adherence |
| US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
| US20030229393A1 (en) * | 2001-03-15 | 2003-12-11 | Kutryk Michael J. B. | Medical device with coating that promotes cell adherence and differentiation |
| US20070055367A1 (en) * | 2000-03-15 | 2007-03-08 | Orbus Medical Technologies, Inc. | Medical device with coating that promotes endothelial cell adherence and differentiation |
| US8460367B2 (en) * | 2000-03-15 | 2013-06-11 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| US6682890B2 (en) | 2000-08-17 | 2004-01-27 | Protein Design Labs, Inc. | Methods of diagnosing and determining prognosis of colorectal cancer |
| DE60140903D1 (en) | 2000-10-18 | 2010-02-04 | Brigham & Womens Hospital | E-SELECTIN / L-SELECTIN-LIGANDEN POLYPEPTIDES OF HEMATOPOETIC CELLS AND METHOD FOR THEIR USE |
| CA2430989A1 (en) | 2000-12-06 | 2002-06-13 | Robert J. Hariri | Method of collecting placental stem cells |
| DE60233248D1 (en) * | 2001-11-15 | 2009-09-17 | Childrens Medical Center | PROCESS FOR THE ISOLATION, EXPANSION AND DIFFERENTIATION OF FEDERAL STRAIN CELLS FROM CHORION ZOTTE, FRUIT WATER AND PLAZENTA AND THERAPEUTIC USES THEREOF |
| CA2474778A1 (en) * | 2002-02-08 | 2003-08-14 | Peter Carmeliet | A novel target to inhibit angiogenesis |
| EP1540348A4 (en) | 2002-08-27 | 2006-10-11 | Stemcells California Inc | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| US7252976B2 (en) * | 2002-08-28 | 2007-08-07 | Board Of Regents The University Of Texas System | Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample |
| EP1583422B1 (en) * | 2002-12-05 | 2016-03-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| US7470538B2 (en) * | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| CA2536067A1 (en) * | 2003-08-27 | 2005-03-10 | Stemcells California, Inc. | Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations |
| WO2005107817A2 (en) * | 2004-04-30 | 2005-11-17 | Orbus Medical Technologies, Inc. | Medical device with coating for capturing genetically-altered cells and methods of using same |
| KR20070034588A (en) * | 2004-06-14 | 2007-03-28 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | CD34 + / CD36 + antibodies that bind to fetal cells but do not bind to adult cells |
| CA2595695A1 (en) | 2005-01-25 | 2006-08-03 | Cell Therapeutics, Inc. | Biologically active protein conjugates comprising (nn[s/t]) peptide repeats and having increased plasma half-life |
| US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| JP5550235B2 (en) | 2005-12-29 | 2014-07-16 | アントフロゲネシス コーポレーション | Placental stem cell population |
| US20070266448A1 (en) * | 2006-05-11 | 2007-11-15 | Alexander Lifke | Method for the production of antibodies |
| EP2084267B1 (en) * | 2006-09-26 | 2018-04-11 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| CA2700436C (en) | 2006-09-28 | 2017-04-18 | John S. Yu | Cancer vaccines and vaccination methods |
| WO2008085229A2 (en) * | 2006-11-15 | 2008-07-17 | Arteriocyte Inc. | Cell-based therapies for treating liver disease |
| EP2318429B1 (en) | 2008-07-28 | 2016-04-20 | Children's Medical Center Corporation | Prominin-1 peptide fragments and uses thereof |
| ES2565779T3 (en) * | 2008-09-02 | 2016-04-06 | Cedars-Sinai Medical Center | CD133 epitopes |
| GB0823553D0 (en) | 2008-12-24 | 2009-01-28 | Immunosolv Ltd | Cell separation technique |
| DK2427485T3 (en) | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | CD133 epitopes |
| JP6046493B2 (en) * | 2010-01-27 | 2016-12-14 | チルドレンズ メディカル センター コーポレーション | Proangin-1 angiogenesis-promoting fragments and uses thereof |
| CA2800488A1 (en) | 2010-05-26 | 2011-12-01 | Regents Of The University Of Minnesota | Single-chain variable fragment anti-cd133 antibodies and uses thereof |
| US9725689B2 (en) | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
| US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
| WO2012109208A2 (en) * | 2011-02-08 | 2012-08-16 | Cellular Dynamics International, Inc. | Hematopoietic precursor cell production by programming |
| ES2707579T3 (en) | 2011-06-01 | 2019-04-04 | Celularity Inc | Pain treatment using placental cytoblast |
| WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
| BR112014020119A2 (en) | 2012-02-13 | 2020-10-27 | Gamida-Cell Ltd | culture of mesenchymal stem cells |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| DK2890498T3 (en) | 2012-08-29 | 2018-05-22 | Inguran Llc | MAGNETIC REMOVAL OR IDENTIFICATION OF DAMAGED OR COMPRIMATED CELLS OR CELL STRUCTURES |
| US10379026B2 (en) | 2012-08-29 | 2019-08-13 | Inguran, Llc | Cell processing using magnetic particles |
| CA2898474A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
| CN105992816B (en) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | Cell amplification in bioreactor |
| JP6783143B2 (en) | 2014-03-25 | 2020-11-11 | テルモ ビーシーティー、インコーポレーテッド | Passive replenishment of medium |
| CN106715676A (en) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | Scheduled feed |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Cell expansion |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| JP7393945B2 (en) | 2017-03-31 | 2023-12-07 | テルモ ビーシーティー、インコーポレーテッド | cell proliferation |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| EP3812769A1 (en) | 2019-10-23 | 2021-04-28 | Unicyte EV AG | A method for in vitro diagnosis of renal glomerular disease or for monitoring the progression of renal glomerular disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
| US5573930A (en) * | 1985-02-05 | 1996-11-12 | Cetus Oncology Corporation | DNA encoding various forms of colony stimulating factor-1 |
| EP0307402B1 (en) * | 1986-05-06 | 1993-08-11 | Genetics Institute, Inc. | Production of m-csf |
| DE68919715T2 (en) | 1988-12-28 | 1995-04-06 | Stefan Miltenyi | METHOD AND MATERIALS FOR HIGHLY GRADUATED MAGNETIC SPLITTING OF BIOLOGICAL MATERIALS. |
| JPH02222686A (en) * | 1989-02-27 | 1990-09-05 | Natl Food Res Inst | Maltotetraose-producing enzyme gene |
| JP3205331B2 (en) * | 1989-03-14 | 2001-09-04 | 和光純薬工業株式会社 | Achromobacter protease I gene and gene product thereof |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| FR2696190B1 (en) * | 1992-09-25 | 1994-12-09 | Agronomique Inst Nat Rech | Nucleic acid coding for an alpha-acetolactate synthase and its applications. |
| DE4314342A1 (en) | 1993-04-30 | 1994-11-03 | Lido Duschabtrennung Prod | Door fitting |
| EP0662512A3 (en) | 1993-12-20 | 1997-01-15 | Becton Dickinson Co | Human hematopoietic stem cells. |
-
1997
- 1997-04-23 US US08/842,382 patent/US6455678B1/en not_active Expired - Lifetime
- 1997-04-25 DK DK97918811T patent/DK0953046T3/en active
- 1997-04-25 JP JP53904597A patent/JP3908279B2/en not_active Expired - Lifetime
- 1997-04-25 AT AT97918811T patent/ATE435282T1/en active
- 1997-04-25 CA CA2251604A patent/CA2251604C/en not_active Expired - Lifetime
- 1997-04-25 AU AU26821/97A patent/AU720938B2/en not_active Expired
- 1997-04-25 WO PCT/US1997/006930 patent/WO1997041224A1/en active Application Filing
- 1997-04-25 EP EP97918811A patent/EP0953046B1/en not_active Expired - Lifetime
- 1997-04-25 DE DE69739480T patent/DE69739480D1/en not_active Expired - Lifetime
- 1997-04-25 ES ES97918811T patent/ES2327691T3/en not_active Expired - Lifetime
-
2001
- 2001-06-13 US US09/881,853 patent/US20010051372A1/en not_active Abandoned
-
2004
- 2004-04-19 US US10/827,907 patent/US20050214861A1/en not_active Abandoned
-
2006
- 2006-01-11 JP JP2006004071A patent/JP2006149396A/en active Pending
- 2006-06-01 JP JP2006153522A patent/JP2006246898A/en active Pending
-
2008
- 2008-07-08 US US12/169,336 patent/US8084033B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111560053A (en) * | 2020-06-17 | 2020-08-21 | 清华大学深圳国际研究生院 | CD133 antagonistic polypeptide, derivative and application thereof |
| CN111560053B (en) * | 2020-06-17 | 2022-05-27 | 清华大学深圳国际研究生院 | CD133 antagonistic polypeptide, derivative and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2327691T3 (en) | 2009-11-02 |
| JP2000509277A (en) | 2000-07-25 |
| JP2006246898A (en) | 2006-09-21 |
| AU2682197A (en) | 1997-11-19 |
| DK0953046T3 (en) | 2009-08-10 |
| US20090093052A1 (en) | 2009-04-09 |
| AU720938B2 (en) | 2000-06-15 |
| US6455678B1 (en) | 2002-09-24 |
| US20010051372A1 (en) | 2001-12-13 |
| EP0953046A1 (en) | 1999-11-03 |
| US20050214861A1 (en) | 2005-09-29 |
| EP0953046B1 (en) | 2009-07-01 |
| CA2251604C (en) | 2012-05-29 |
| ATE435282T1 (en) | 2009-07-15 |
| WO1997041224A1 (en) | 1997-11-06 |
| JP3908279B2 (en) | 2007-04-25 |
| DE69739480D1 (en) | 2009-08-13 |
| US8084033B2 (en) | 2011-12-27 |
| JP2006149396A (en) | 2006-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2251604A1 (en) | Human hematopoietic stem and progenitor cell antigen and methods for its use | |
| Robinson | 100-kD coated vesicle proteins: molecular heterogeneity and intracellular distribution studied with monoclonal antibodies | |
| Malissen et al. | Nucleotide sequence of a light chain gene of the mouse IA subregion: Aβd | |
| Krause et al. | Characterization of murine CD34, a marker for hematopoietic progenitor and stem cells | |
| AU2005255024C1 (en) | Antibodies binding to CD34+/CD36+ fetal but not to adult cells | |
| JP3070865B2 (en) | Subset of human progenitor cells | |
| Kaneko et al. | Ferritin immunohistochemistry as a marker for microglia | |
| AU642938B2 (en) | Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1) | |
| van Epps et al. | Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes. | |
| US7718376B2 (en) | Identification and isolation of somatic stem cells and uses thereof | |
| LaRochelle et al. | Molecular localization of the transforming and secretory properties of PDGF A and PDGF B | |
| CA2215394A1 (en) | Il-17 receptor | |
| Wognum et al. | Detection and isolation of the erythropoietin receptor using biotinylated erythropoietin | |
| CA2316280A1 (en) | Novel g protein-coupled receptor | |
| Feller et al. | Enzymehistochemical staining of Tμ lymphocytes for glycyl‐proline‐4‐methoxy‐beta‐naphthylamide‐peptidase (DAP IV) | |
| Strobl et al. | Antigenic analysis of human haemopoietic progenitor cells expressing the growth factor receptor c‐kit | |
| Cook et al. | Human aminoacylase-1. Cloning, sequence, and expression analysis of a chromosome 3p21 gene inactivated in small cell lung cancer | |
| Quackenbush et al. | Confirmation by peptide sequence and co-expression on various cell types of the identity of CD44 and P85 glycoprotein | |
| Van Der Loo et al. | Identification of hematopoietic stem cell subsets on the basis of their primitiveness using antibody ER-MP12 | |
| CA2240409A1 (en) | Mammalian cx3c chemokine genes | |
| EP1394263B1 (en) | Methods for detection and separation of undifferentiated hepatic cells using dlk | |
| JPH11506939A (en) | Secretory leader trap cloning | |
| Endo et al. | Two chronic myelogenous leultaemia cell lines which represent different stages of erythroid differentiation | |
| Gonzalez et al. | Immunolocalization of V1 vasopressin receptors in the rat kidney using anti-receptor antibodies | |
| Chin-Yee et al. | Current status of CD34+ cell analysis by flow cytometry: the ISHAGE guidelines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20170425 |